引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1981次   下载 125 本文二维码信息
码上扫一扫!
0.03%他克莫司软膏治疗儿童慢性唇炎疗效观察
杨敏,郑惠文,李云玲
0
(浙江大学医学院附属儿童医院,浙江杭州 310052)
摘要:
目的:探讨0.03%他克莫司软膏治疗儿童慢性唇炎的疗效与安全性。方法:选择2017年11月至2018年12月在我院确诊的慢性唇炎患儿45例,按随机数表法分为观察组23例和对照组22例,分别外用0.03%他克莫司软膏和0.1%丁酸氢化可的松软膏治疗,均每日2次,连续治疗3周,观察两组患儿治疗第1、2、3周的临床疗效及治疗结束后第1、2、3个月的复发情况。结果:观察组失访2例,未纳入结果统计。治疗第1、2、3周观察组的总有效率分别为38.1%、71.4%、85.7%,对照组分别为40.9%、68.2%、90.9%,两组比较差异均无统计学意义(P均>0.05)。治疗结束后第1、2、3个月的复发率观察组分别为9.5%、14.3%、23.8%,对照组分别为22.7%、45.5%、54.5%,观察组第2、3个月的复发率均低于对照组(P均<0.05)。观察组患儿主要不良反应为用药部位灼热、刺痛感等一过性不适,治疗前后实验室检查未发现异常改变。结论:0.03%他克莫司软膏治疗儿童慢性唇炎安全、有效且复发率低。
关键词:  儿童  他克莫司  慢性唇炎
DOI:
基金项目:
0.03% Tacrolimus Ointment in the Treatment of Chronic Cheilitis in Children
Yang Min, Zheng Huiwen, Li Yunling
(The Children’s Hospital, Zhejiang University School of Medicine, Zhejiang Hangzhou 310052, China)
Abstract:
Objective: To probe into the efficacy and safety of tacrolimus 0.03% ointment in the treatment of chronic cheilitis in children. Methods: Forty-five children with chronic cheilitis admitted into our hospital from Nov. 2017 to Dec. 2018 were extracted to be divided into the observation group (n=23) and the control group (n=22) via the random number table. The observation group and control group were treated with 0.03% tacrolimus ointment and 0.1% hydrocortisone butyrate ointment, respectively, twice a day for 3 weeks. The clinical efficacy of the first, second, and third weeks of treatment and the recurrence of the first, second, and third months after the treatment were observed in two groups. Results: Two cases were lost to follow-up in the observation group, which were not included in the statistics. In the first, second and third weeks of treatment, the total effective rates of the observation group were respectively 38.1%, 71.4% and 85.7%, and those of the control group were respectively 40.9%, 68.2% and 90.9%, there was no statistically significant difference between two groups (P>0.05). The recurrence rates in the first, second and third months after treatment were 9.5%, 14.3% and 23.8% in the observation group, and 22.7%, 45.5% and 54.5% in the control group, respectively. The recurrence rates in the second and third months in the observation group were lower than those in the control group (P<0.05). The main adverse drug reactions of the observation group were transient discomfort such as burning and stinging at the site of medication, and no abnormal changes were found in laboratory examination before and after treatment. Conclusion: 0.03% tacrolimus ointment is safe, effective and has lower recurrence external application medication for treatment of children with chronic cheilitis.
Key words:  children  tacrolimus  chronic cheilitis

用微信扫一扫

用微信扫一扫